Irinotecan and Bevacizumab for Recurrent Ovarian Cancer
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the
treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when
combined with bevacizumab.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health